WO2003064383A2 - Phosphorus-containing compounds & uses thereof - Google Patents
Phosphorus-containing compounds & uses thereof Download PDFInfo
- Publication number
- WO2003064383A2 WO2003064383A2 PCT/US2003/003030 US0303030W WO03064383A2 WO 2003064383 A2 WO2003064383 A2 WO 2003064383A2 US 0303030 W US0303030 W US 0303030W WO 03064383 A2 WO03064383 A2 WO 03064383A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- moiety
- independently
- occurrence
- aryl
- Prior art date
Links
- 0 C[C@](Cc(cc1)cc(OC)c1OI)[C@](CC([C@](C)C=C(C)[C@]([C@](C([C@](C)C[C@](C)C=CC=CC=C(C)[C@](*)CC(CC[C@]1C)*[C@]1(C(C(N1C2CCCC1)=O)=O)O)=O)OC)O)=O)OC2=O Chemical compound C[C@](Cc(cc1)cc(OC)c1OI)[C@](CC([C@](C)C=C(C)[C@]([C@](C([C@](C)C[C@](C)C=CC=CC=C(C)[C@](*)CC(CC[C@]1C)*[C@]1(C(C(N1C2CCCC1)=O)=O)O)=O)OC)O)=O)OC2=O 0.000 description 4
- UDQGDAHTUQCRBY-PEZBUJJGSA-N CC(C)(C)/C=C(/CCc1ccccc1)\CCOC Chemical compound CC(C)(C)/C=C(/CCc1ccccc1)\CCOC UDQGDAHTUQCRBY-PEZBUJJGSA-N 0.000 description 1
- NVDFYFKMMZFUNE-UHFFFAOYSA-N CC(C)(C)N1OCCCO1 Chemical compound CC(C)(C)N1OCCCO1 NVDFYFKMMZFUNE-UHFFFAOYSA-N 0.000 description 1
- OGTRQDOKNDBMMV-UHFFFAOYSA-N CC(C)(C[O]1CCOCCNC)P1(OCCOCCOC)=O Chemical compound CC(C)(C[O]1CCOCCNC)P1(OCCOCCOC)=O OGTRQDOKNDBMMV-UHFFFAOYSA-N 0.000 description 1
- CGNVCNBGLPQQDZ-NJNHOYGRSA-N CCCOP(C)(O[C@H](CC[C@@H](C[C@@H](C)[C@H](CC([C@H](C)/C=C(\C)/[C@H]([C@H](C(C(C)C[C@H](C)/C=C/C=C/C=C(\C)/[C@H](C[C@H](CC[C@H]1C)O[C@]1(C(C(N1C2CCCC1)=O)=O)O)OC)=O)OC)O)=O)OC2=O)C1)[C@@H]1OC)=O Chemical compound CCCOP(C)(O[C@H](CC[C@@H](C[C@@H](C)[C@H](CC([C@H](C)/C=C(\C)/[C@H]([C@H](C(C(C)C[C@H](C)/C=C/C=C/C=C(\C)/[C@H](C[C@H](CC[C@H]1C)O[C@]1(C(C(N1C2CCCC1)=O)=O)O)OC)=O)OC)O)=O)OC2=O)C1)[C@@H]1OC)=O CGNVCNBGLPQQDZ-NJNHOYGRSA-N 0.000 description 1
- BUROJSBIWGDYCN-XTRHDYNXSA-N C[C@H](CC(CC[C@H]1OP(C)(C)=O)CC1OC)[C@H](CC([C@H](C)/C=C(\C)/C([C@H](C(C(C)C[C@H](C)/C=C/C=C/C=C(\C)/[C@H](C[C@H](CCC1C)OC1(C(C(N1C2CCCC1)=O)=O)O)OC)=O)OC)O)=O)OC2=O Chemical compound C[C@H](CC(CC[C@H]1OP(C)(C)=O)CC1OC)[C@H](CC([C@H](C)/C=C(\C)/C([C@H](C(C(C)C[C@H](C)/C=C/C=C/C=C(\C)/[C@H](C[C@H](CCC1C)OC1(C(C(N1C2CCCC1)=O)=O)O)OC)=O)OC)O)=O)OC2=O BUROJSBIWGDYCN-XTRHDYNXSA-N 0.000 description 1
- ONPZMTBFHFTVIN-UHFFFAOYSA-N OC(C1SCCCC1)=O Chemical compound OC(C1SCCCC1)=O ONPZMTBFHFTVIN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003564006A JP4547911B2 (ja) | 2002-02-01 | 2003-02-03 | リン含有化合物およびその用途 |
AU2003210787A AU2003210787B2 (en) | 2002-02-01 | 2003-02-03 | Phosphorus-containing compounds & uses thereof |
DK03735110T DK1478648T3 (da) | 2002-02-01 | 2003-02-03 | Phosphorholdige forbindelser og anvendelser deraf |
KR20047011867A KR100956195B1 (ko) | 2002-02-01 | 2003-02-03 | 인 함유 화합물 및 이의 용도 |
MXPA04007402A MXPA04007402A (es) | 2002-02-01 | 2003-02-03 | Compuestos que contienen fosforo y usos de los mismos. |
BR0307544A BR0307544A (pt) | 2002-02-01 | 2003-02-03 | Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos |
EP20030735110 EP1478648B1 (en) | 2002-02-01 | 2003-02-03 | Phosphorus-containing compounds and uses thereof |
IL16273403A IL162734A0 (en) | 2002-02-01 | 2003-02-03 | Phosphorus-containing compounds & uses thereof |
EA200401008A EA008379B1 (ru) | 2002-02-01 | 2003-02-03 | Фосфорсодержащие соединения и их применения |
ES03735110.3T ES2485841T3 (es) | 2002-02-01 | 2003-02-03 | Compuestos que contienen fósforo y usos de los mismos |
CA2472341A CA2472341C (en) | 2002-02-01 | 2003-02-03 | Phosphorus-containing compounds & uses thereof |
IL162734A IL162734A (en) | 2002-02-01 | 2004-06-24 | Compounds containing phosphorus and their use |
IL199153A IL199153A (en) | 2002-02-01 | 2009-06-04 | Compounds containing phosphorus and their use |
AU2009202913A AU2009202913B2 (en) | 2002-02-01 | 2009-07-20 | Phosphorus-containing compounds & uses thereof |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35325202P | 2002-02-01 | 2002-02-01 | |
US60/353,252 | 2002-02-01 | ||
US42692802P | 2002-11-15 | 2002-11-15 | |
US60/426,928 | 2002-11-15 | ||
US42838302P | 2002-11-22 | 2002-11-22 | |
US60/428,383 | 2002-11-22 | ||
US43393002P | 2002-12-17 | 2002-12-17 | |
US60/433,930 | 2002-12-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003064383A2 true WO2003064383A2 (en) | 2003-08-07 |
WO2003064383A3 WO2003064383A3 (en) | 2004-01-22 |
Family
ID=27671080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/003030 WO2003064383A2 (en) | 2002-02-01 | 2003-02-03 | Phosphorus-containing compounds & uses thereof |
Country Status (16)
Cited By (202)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004096236A2 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Immunomodulator phosphonate conjugates |
WO2005049021A1 (en) * | 2003-11-03 | 2005-06-02 | Oy Helsinki Transplantation R & D Ltd | Materials and methods for inhibiting neointimal hyperplasia |
WO2005053661A2 (en) * | 2003-12-01 | 2005-06-16 | Novartis Ag | Pharmaceutical combinations |
EP1543850A1 (en) * | 2003-12-17 | 2005-06-22 | Cordis Neurovascular, Inc. | Activatable bioactive implantable medical device |
EP1543849A1 (en) * | 2003-12-17 | 2005-06-22 | Cordis Neurovascular, Inc. | Activatable bioactive implantable medical device |
EP1648900A2 (en) * | 2003-07-11 | 2006-04-26 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing macrocycles |
US7091213B2 (en) | 2002-02-01 | 2006-08-15 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing compounds and uses thereof |
WO2006128660A1 (en) * | 2005-05-31 | 2006-12-07 | Novartis Ag | Combination of hmg-coa reductase inhibitors amd mtor inhibitors |
US7244261B2 (en) | 2004-04-08 | 2007-07-17 | Cordis Neurovascular, Inc. | Activatable bioactive vascular occlusive device |
US7273717B2 (en) | 2003-10-24 | 2007-09-25 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B |
US7300924B2 (en) | 2003-04-25 | 2007-11-27 | Gilead Sciences, Inc. | Anti-infective phosphonate analogs |
WO2007135411A1 (en) * | 2006-05-19 | 2007-11-29 | Biotica Technology Ltd. | 39-desmethoxy-39-methyl derivatives of rapamycin. |
WO2008033956A2 (en) | 2006-09-13 | 2008-03-20 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
JP2008532991A (ja) * | 2005-03-11 | 2008-08-21 | バイオティカ テクノロジー リミテッド | ラパマイシンの39−デスメトキシ誘導体 |
US7417055B2 (en) | 2003-04-25 | 2008-08-26 | Gilead Sciences, Inc. | Kinase inhibitory phosphonate analogs |
US7427636B2 (en) | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
US7427624B2 (en) | 2003-10-24 | 2008-09-23 | Gilead Sciences, Inc. | Purine nucleoside phosphorylase inhibitory phosphonate compounds |
US7429565B2 (en) | 2003-04-25 | 2008-09-30 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
US7432273B2 (en) | 2003-10-24 | 2008-10-07 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
US7432272B2 (en) | 2003-12-22 | 2008-10-07 | Gilead Sciences, Inc. | Antiviral analogs |
US7432277B2 (en) | 2002-02-01 | 2008-10-07 | Araid Gene Therapeutics, Inc. | Phosphorus-containing macrocycles |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
US7462608B2 (en) | 2002-04-26 | 2008-12-09 | Gilead Sciences, Inc. | Non nucleoside reverse transcriptase inhibitors |
US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
EP2022498A2 (en) | 2005-11-21 | 2009-02-11 | Novartis AG | Neuroendocrine tumour treatment |
WO2009054001A1 (en) * | 2007-10-22 | 2009-04-30 | Biocon Limited | A pharmaceutical composition and a process thereof |
US7645747B2 (en) | 2003-04-25 | 2010-01-12 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
EP2206704A1 (en) | 2005-04-19 | 2010-07-14 | Novartis AG | Pharmaceutically active diazepanes |
WO2011002887A1 (en) | 2009-07-02 | 2011-01-06 | Schering Corporation | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS |
WO2011024168A2 (en) | 2009-08-26 | 2011-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd | Sustained release delivery systems for the prevention and treatment of head and neck cancers |
WO2011050016A1 (en) | 2009-10-23 | 2011-04-28 | Eli Lilly And Company | Akt inhibitors |
EP2332577A1 (en) | 2005-10-26 | 2011-06-15 | Novartis AG | Novel use of IL-1beta compounds |
WO2011120911A1 (en) | 2010-03-30 | 2011-10-06 | Novartis Ag | Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling |
US8088789B2 (en) | 2006-09-13 | 2012-01-03 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
WO2012022814A1 (en) | 2010-08-20 | 2012-02-23 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
WO2012027236A1 (en) | 2010-08-23 | 2012-03-01 | Schering Corporation | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
WO2012061907A2 (en) | 2010-11-10 | 2012-05-18 | Katholieke Universiteit Leuven | Osteoclast activity |
EP2455104A1 (en) | 2010-11-19 | 2012-05-23 | Universitätsklinikum Freiburg | Bio-functionalized stimulus-responsive dissolvable PEG-hydrogels |
EP2468301A1 (en) | 2007-05-29 | 2012-06-27 | Novartis AG | New indications for anti-IL-1-beta therapy |
WO2012145471A1 (en) | 2011-04-21 | 2012-10-26 | Merck Sharp & Dohme Corp. | Insulin-like growth factor-1 receptor inhibitors |
WO2013016164A1 (en) | 2011-07-26 | 2013-01-31 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS |
WO2013082282A1 (en) | 2011-12-02 | 2013-06-06 | lNOVARTIS AG | Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease. |
WO2013084147A2 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
WO2013084138A1 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Cyclic urea derivatives as androgen receptor antagonists |
WO2013084148A2 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
WO2013105022A2 (en) | 2012-01-09 | 2013-07-18 | Novartis Ag | Organic compositions to treat beta-catenin-related diseases |
US8496967B2 (en) | 2006-11-14 | 2013-07-30 | Ariad Pharmaceuticals, Inc. | Oral formulations |
US8507518B2 (en) | 2003-11-04 | 2013-08-13 | Mayo Foundation For Medical Education And Research | Method of treating mantle cell lymphoma |
WO2013138871A1 (en) | 2012-03-23 | 2013-09-26 | The University Of Queensland | Immunomodulatory agent and uses therefor |
EP2662082A1 (en) | 2005-11-14 | 2013-11-13 | Ariad Pharmaceuticals, Incorporated | Administration of mTOR inhibitors |
EP2762142A1 (en) | 2009-10-30 | 2014-08-06 | ARIAD Pharmaceuticals, Inc. | Compositions for treating cancer |
WO2014130657A1 (en) | 2013-02-20 | 2014-08-28 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
WO2014153270A1 (en) | 2013-03-16 | 2014-09-25 | Novartis Ag | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor |
WO2014160160A2 (en) | 2013-03-13 | 2014-10-02 | Novartis Ag | Antibody drug conjugates |
WO2014184734A1 (en) | 2013-05-14 | 2014-11-20 | Novartis Ag | Markers associated with mtor inhibition |
US8921642B2 (en) | 2008-01-11 | 2014-12-30 | Massachusetts Eye And Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
US8951986B2 (en) | 2008-07-08 | 2015-02-10 | Gilead Sciences, Inc. | Salts of HIV inhibitor compounds |
WO2015044854A1 (en) | 2013-09-24 | 2015-04-02 | Novartis Ag | Markers associated with mtor inhibition |
EP2878312A1 (en) | 2013-12-02 | 2015-06-03 | Albert-Ludwigs-Universität Freiburg | Reversible PEGylation of nanocarriers |
WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
WO2015090230A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
WO2015107495A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
WO2015107493A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
WO2015187541A1 (en) | 2014-06-02 | 2015-12-10 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
WO2016024195A1 (en) | 2014-08-12 | 2016-02-18 | Novartis Ag | Anti-cdh6 antibody drug conjugates |
WO2016040892A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies |
WO2016044605A1 (en) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
WO2016054555A2 (en) | 2014-10-03 | 2016-04-07 | Novartis Ag | Combination therapies |
WO2016057705A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
WO2016057841A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Compositions and methods of use for augmented immune response and cancer therapy |
WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
WO2016075670A1 (en) | 2014-11-14 | 2016-05-19 | Novartis Ag | Antibody drug conjugates |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
WO2016151499A1 (en) | 2015-03-25 | 2016-09-29 | Novartis Ag | Formylated n-heterocyclic derivatives as fgfr4 inhibitors |
US9457035B2 (en) | 2004-07-27 | 2016-10-04 | Gilead Sciences, Inc. | Antiviral compounds |
WO2016164731A2 (en) | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
WO2016164580A1 (en) | 2015-04-07 | 2016-10-13 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
WO2016203432A1 (en) | 2015-06-17 | 2016-12-22 | Novartis Ag | Antibody drug conjugates |
WO2016203405A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2016203406A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2016203404A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2017015427A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
WO2017019894A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
WO2017072662A1 (en) | 2015-10-29 | 2017-05-04 | Novartis Ag | Antibody conjugates comprising toll-like receptor agonist |
WO2017079115A1 (en) | 2015-11-03 | 2017-05-11 | Janssen Biotech, Inc. | Antibodies specifically binding tim-3 and their uses |
WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
WO2017112741A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2018057585A1 (en) | 2016-09-21 | 2018-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use |
WO2018064076A1 (en) | 2016-09-27 | 2018-04-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
EP3360870A1 (en) | 2013-02-19 | 2018-08-15 | Novartis AG | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
WO2018163051A1 (en) | 2017-03-06 | 2018-09-13 | Novartis Ag | Methods of treatment of cancer with reduced ubb expression |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
WO2018198091A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Antibody conjugates comprising toll-like receptor agonist and combination therapies |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
WO2018215938A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
WO2018215936A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
WO2018226336A1 (en) | 2017-06-09 | 2018-12-13 | Providence Health & Services - Oregon | Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer |
WO2018237157A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
WO2019051469A1 (en) | 2017-09-11 | 2019-03-14 | Krouzon Pharmaceuticals, Inc. | SHP2 OCTAHYDROCYCLOPENTA [C] PYRROLE ALLOSTERIC INHIBITORS |
WO2019067328A1 (en) | 2017-09-26 | 2019-04-04 | Cero Therapeutics, Inc. | CHIMERIC ENGINEERING RECEPTOR MOLECULES AND METHODS OF USE |
WO2019108900A1 (en) | 2017-11-30 | 2019-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
EP3514178A1 (en) | 2013-03-15 | 2019-07-24 | Novartis AG | Antibody drug conjugates |
EP3514179A1 (en) | 2014-01-24 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
WO2019152660A1 (en) | 2018-01-31 | 2019-08-08 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
EP3539990A1 (en) | 2014-07-16 | 2019-09-18 | Dana-Farber Cancer Institute, Inc. | Her3 inhibition in low-grade serous cancers |
WO2019191339A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof |
WO2019191334A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
WO2019191340A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Cellular immunotherapy compositions and uses thereof |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
WO2019224718A2 (en) | 2018-05-24 | 2019-11-28 | Janssen Biotech, Inc. | Psma binding agents and uses thereof |
WO2019229701A2 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
WO2019229658A1 (en) | 2018-05-30 | 2019-12-05 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
WO2019241426A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
WO2020012337A1 (en) | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases |
WO2020012334A1 (en) | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
WO2020021322A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) Srl | Stable, concentrated radionuclide complex solutions |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
US10577362B2 (en) | 2016-05-04 | 2020-03-03 | Genoscience Pharma | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases |
WO2020061103A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
WO2020069409A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
WO2020069405A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
WO2020068873A1 (en) | 2018-09-25 | 2020-04-02 | Black Diamond Therapeutics, Inc. | Tyrosine kinase inhibitor compositions, methods of making and methods of use |
WO2020064693A1 (en) | 2018-09-25 | 2020-04-02 | Advanced Accelerator Applications (Italy) Srl | Combination therapy |
WO2020065453A1 (en) | 2018-09-29 | 2020-04-02 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
WO2020088631A1 (en) | 2018-11-01 | 2020-05-07 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
EP3660042A1 (en) | 2014-07-31 | 2020-06-03 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
US10695327B2 (en) | 2006-09-13 | 2020-06-30 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
WO2020198077A1 (en) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
EP3722316A1 (en) | 2014-07-21 | 2020-10-14 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
US10851125B2 (en) | 2017-08-01 | 2020-12-01 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate |
WO2021003417A1 (en) | 2019-07-03 | 2021-01-07 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
WO2021030711A1 (en) | 2019-08-15 | 2021-02-18 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
WO2021067875A1 (en) | 2019-10-03 | 2021-04-08 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
US11034672B1 (en) | 2018-09-25 | 2021-06-15 | Black Diamond Therapeutics, Inc. | Tyrosine kinase inhibitor compositions, methods of making and methods of use |
WO2021123996A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
WO2021183318A2 (en) | 2020-03-09 | 2021-09-16 | President And Fellows Of Harvard College | Methods and compositions relating to improved combination therapies |
WO2021195206A1 (en) | 2020-03-24 | 2021-09-30 | Black Diamond Therapeutics, Inc. | Polymorphic forms and related uses |
WO2021220170A1 (en) | 2020-04-29 | 2021-11-04 | Novartis Ag | Compounds and compositions for inhibiting the activity of hif2-alpha and their methods of use |
WO2021242794A2 (en) | 2020-05-29 | 2021-12-02 | President And Fellows Of Harvard College | Living cells engineered with polyphenol-functionalized biologically active nanocomplexes |
WO2021252920A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2021262969A1 (en) | 2020-06-24 | 2021-12-30 | The General Hospital Corporation | Materials and methods of treating cancer |
WO2022029573A1 (en) | 2020-08-03 | 2022-02-10 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2022036265A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Chimeric tim receptors and uses thereof |
WO2022036287A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Anti-cd72 chimeric receptors and uses thereof |
WO2022036285A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase |
WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
WO2022123316A1 (en) | 2020-12-09 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
WO2022140472A1 (en) | 2020-12-22 | 2022-06-30 | Nikang Therapeutics, Inc. | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway |
WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
WO2022162518A2 (en) | 2021-01-28 | 2022-08-04 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
WO2022170052A1 (en) | 2021-02-05 | 2022-08-11 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof |
WO2022183072A1 (en) | 2021-02-26 | 2022-09-01 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
WO2022215011A1 (en) | 2021-04-07 | 2022-10-13 | Novartis Ag | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
WO2022219407A1 (en) | 2021-04-14 | 2022-10-20 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
WO2022219412A1 (en) | 2021-04-14 | 2022-10-20 | Monte Rosa Therapeutics Ag | Isoindolinone amide compounds useful to treat diseases associated with gspt1 |
WO2022221227A1 (en) | 2021-04-13 | 2022-10-20 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
WO2022243846A1 (en) | 2021-05-18 | 2022-11-24 | Novartis Ag | Combination therapies |
WO2022261018A1 (en) | 2021-06-07 | 2022-12-15 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
WO2023288046A1 (en) | 2021-07-15 | 2023-01-19 | President And Fellows Of Harvard College | Compositions and methods relating to cells with adhered particles |
WO2023284730A1 (en) | 2021-07-14 | 2023-01-19 | Nikang Therapeutics, Inc. | Alkylidene derivatives as kras inhibitors |
WO2023010097A1 (en) | 2021-07-28 | 2023-02-02 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
US11746103B2 (en) | 2020-12-10 | 2023-09-05 | Sumitomo Pharma Oncology, Inc. | ALK-5 inhibitors and uses thereof |
WO2023192801A1 (en) | 2022-03-28 | 2023-10-05 | Nikang Therapeutics, Inc. | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2023240024A1 (en) | 2022-06-08 | 2023-12-14 | Nikang Therapeutics, Inc. | Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors |
WO2024023666A1 (en) | 2022-07-26 | 2024-02-01 | Novartis Ag | Crystalline forms of an akr1c3 dependent kars inhibitor |
EP4324518A2 (en) | 2014-01-31 | 2024-02-21 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040073294A1 (en) | 2002-09-20 | 2004-04-15 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
EP1521828B1 (en) * | 2002-07-16 | 2015-07-01 | Buck Institute for Research on Aging | Production of polyketides |
US8980870B2 (en) * | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
US20040202789A1 (en) * | 2003-03-31 | 2004-10-14 | Council Of Scientific And Industrila Research | Process for preparing thin film solids |
US20060173033A1 (en) * | 2003-07-08 | 2006-08-03 | Michaela Kneissel | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
US20050049693A1 (en) * | 2003-08-25 | 2005-03-03 | Medtronic Vascular Inc. | Medical devices and compositions for delivering biophosphonates to anatomical sites at risk for vascular disease |
US7294123B2 (en) * | 2003-12-17 | 2007-11-13 | Corris Neurovascular, Inc. | Activatable bioactive vascular occlusive device and method of use |
US20050187608A1 (en) * | 2004-02-24 | 2005-08-25 | O'hara Michael D. | Radioprotective compound coating for medical devices |
CA2561717A1 (en) * | 2004-05-17 | 2005-11-24 | Novartis Ag | Combination of organic compounds |
ATE493973T1 (de) | 2004-06-04 | 2011-01-15 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
US8075904B2 (en) * | 2004-08-11 | 2011-12-13 | California Institute Of Technology | High aspect ratio template and method for producing same for central and peripheral nerve repair |
US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
US20060088596A1 (en) | 2004-09-28 | 2006-04-27 | Atrium Medical Corporation | Solubilizing a drug for use in a coating |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
EP1811935B1 (en) | 2004-09-28 | 2016-03-30 | Atrium Medical Corporation | Heat cured gel and method of making |
US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
MX2007003790A (es) * | 2004-09-30 | 2007-05-24 | Ariad Gene Therapeutics Inc | Metodo de tratamiento. |
CN102886045A (zh) * | 2005-02-03 | 2013-01-23 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
US8071574B2 (en) | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
GB0504995D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Use of a compound |
US20100061994A1 (en) * | 2005-03-11 | 2010-03-11 | Rose Mary Sheridan | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
US20070071754A1 (en) * | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Method to ameliorate inflammation |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
AU2006304590A1 (en) * | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
KR101354828B1 (ko) * | 2005-11-04 | 2014-02-18 | 와이어쓰 엘엘씨 | mTOR 저해자, 헤르셉틴, 및/또는 HKI-272의항신생물성 조합 |
MX2008008152A (es) | 2005-12-23 | 2008-09-12 | Ariad Pharma Inc | Compuestos heterociclicos biciclicos. |
DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
JP2010500283A (ja) * | 2006-05-31 | 2010-01-07 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法 |
JP2009539769A (ja) * | 2006-06-02 | 2009-11-19 | アリアド ジーン セラピューティクス インコーポレイテッド | カペシタビン併用療法 |
US20100266590A1 (en) * | 2006-08-02 | 2010-10-21 | Demetri George D | Combination therapy |
BRPI0719883A2 (pt) | 2006-10-09 | 2015-05-05 | Takeda Pharmaceutical | Inibidores de quinase |
US10059756B2 (en) | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
US8642031B2 (en) * | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
EP2626091B1 (en) | 2006-11-06 | 2016-09-28 | Atrium Medical Corporation | Coated surgical mesh |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
US8466096B2 (en) * | 2007-04-26 | 2013-06-18 | Afton Chemical Corporation | 1,3,2-dioxaphosphorinane, 2-sulfide derivatives for use as anti-wear additives in lubricant compositions |
US8142702B2 (en) * | 2007-06-18 | 2012-03-27 | Molecular Imprints, Inc. | Solvent-assisted layer formation for imprint lithography |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
US20110104052A1 (en) * | 2007-12-03 | 2011-05-05 | The Johns Hopkins University | Methods of synthesis and use of chemospheres |
US9002344B2 (en) * | 2007-12-05 | 2015-04-07 | Microsoft Technology Licensing, Llc | Phone content service |
US20090253733A1 (en) * | 2008-04-02 | 2009-10-08 | Biointeractions, Ltd. | Rapamycin carbonate esters |
US20110098241A1 (en) * | 2008-04-14 | 2011-04-28 | Poniard Pharmaceuticals, Inc. | Rapamycin analogs as anti-cancer agents |
DK2300013T3 (en) | 2008-05-21 | 2017-12-04 | Ariad Pharma Inc | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS |
EP3135285B1 (en) | 2008-06-17 | 2018-08-15 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
KR101138294B1 (ko) | 2008-09-24 | 2012-04-25 | 김형일 | 혈관벽 임시 골격용 생분해성 블랜드 |
EP2365809B8 (en) | 2008-11-12 | 2018-10-10 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
US20120129809A1 (en) * | 2009-03-02 | 2012-05-24 | Merck & Co., | Lung cancer treatment |
WO2010120599A2 (en) | 2009-04-16 | 2010-10-21 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
AU2010300925A1 (en) | 2009-09-30 | 2012-03-29 | Merck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
EP2593141B1 (en) | 2010-07-16 | 2018-07-04 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
US8716363B2 (en) | 2011-09-28 | 2014-05-06 | Globus Medical, Inc. | Biodegradable putty compositions and implant devices, methods, and kits relating to the same |
EP2589383A1 (en) | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
TW201408682A (zh) | 2012-08-22 | 2014-03-01 | Chunghwa Chemical Synthesis & Biotech Co Ltd | 高轉化率之42-(二甲基亞磷醯)雷帕霉素的製備方法 |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
CN105073112B (zh) | 2013-03-13 | 2017-12-29 | 参天制药株式会社 | 睑板腺功能障碍的治疗剂 |
US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
CA2929181A1 (en) | 2013-11-13 | 2015-05-21 | Novartis Ag | Mtor inhibitors for enhancing the immune response |
WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
ES2900426T3 (es) | 2013-12-31 | 2022-03-16 | Rapamycin Holdings Llc | Preparaciones orales y uso de nanopartículas de rapamicina |
WO2015142661A1 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
IL293603B2 (en) | 2014-04-07 | 2024-03-01 | Novartis Ag | Cancer treatment using chimeric antigen receptor (CAR) against CD19 |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
BR112016029662B1 (pt) | 2014-06-19 | 2023-10-24 | Takeda Pharmaceutical Company Limited | COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
US10377818B2 (en) | 2015-01-30 | 2019-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating glioma |
US10576076B2 (en) | 2015-05-20 | 2020-03-03 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
EP3373927A1 (en) | 2015-11-11 | 2018-09-19 | Novartis AG | Uses of myostatin antagonists, combinations containing them and uses thereof |
JP6510726B2 (ja) * | 2016-02-29 | 2019-05-08 | 富士フイルム株式会社 | 平版印刷版原版及び平版印刷版の製版方法 |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
WO2018017708A1 (en) | 2016-07-20 | 2018-01-25 | University Of Utah Research Foundation | Cd229 car t cells and methods of use thereof |
WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
CA3044355A1 (en) | 2016-11-23 | 2018-05-31 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
US20210009613A1 (en) | 2017-12-12 | 2021-01-14 | Shenzhen Targetrx, Inc. | Arylphosphine oxides for inhibiting kinase activity |
JP7043098B2 (ja) | 2017-12-21 | 2022-03-29 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | キナーゼ活性を阻害するためのジアニリノピリミジン系化合物 |
WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
CN110407872A (zh) * | 2019-07-25 | 2019-11-05 | 江苏好收成韦恩农化股份有限公司 | 烷基氯化膦酸单烷酯联产高纯度三氯氧磷的方法 |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5310903A (en) | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | Imidazolidyl rapamycin derivatives |
WO1994018317A1 (en) | 1993-02-12 | 1994-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
WO1995002684A1 (en) | 1993-07-16 | 1995-01-26 | The Board Of Trustees Of The Leland Stanford Junior University | Regulated apoptosis |
US5525610A (en) | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
US5527907A (en) | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
WO1998009972A1 (en) | 1996-09-09 | 1998-03-12 | American Home Products Corporation | Rapamycin derivatives with unnatural stereochemistries |
WO1999036553A2 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
WO2001004387A1 (en) | 1999-07-12 | 2001-01-18 | Semitool, Inc. | Lift and rotate assembly for use in a workpiece processing station and a method of attaching the same |
WO2001014387A1 (en) | 1999-08-24 | 2001-03-01 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
US6471980B2 (en) | 2000-12-22 | 2002-10-29 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
Family Cites Families (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3976071A (en) | 1974-01-07 | 1976-08-24 | Dynatech Corporation | Methods of improving control of release rates and products useful in same |
US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
US4335094A (en) | 1979-01-26 | 1982-06-15 | Mosbach Klaus H | Magnetic polymer particles |
US4345588A (en) | 1979-04-23 | 1982-08-24 | Northwestern University | Method of delivering a therapeutic agent to a target capillary bed |
US4357925A (en) | 1980-12-17 | 1982-11-09 | The Bendix Corporation | Distributor injection pump for diesel engines |
WO1983001738A1 (en) | 1981-11-12 | 1983-05-26 | SCHRÖDER, Ulf | Intravascularly administrable, magnetically responsive nanosphere or manoparticle, a process for the production thereof, and the use thereof |
US5206159A (en) | 1984-11-01 | 1993-04-27 | Miles Inc., As Legal Successor By Merger With Technicon Instruments Corp. | Polymer particles containing colloidal iron oxide granules for use as a magnetically responsive reagent carrier |
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
GB8601100D0 (en) | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
US4871716A (en) | 1986-02-04 | 1989-10-03 | University Of Florida | Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof |
US5000185A (en) | 1986-02-28 | 1991-03-19 | Cardiovascular Imaging Systems, Inc. | Method for intravascular two-dimensional ultrasonography and recanalization |
US4832686A (en) | 1986-06-24 | 1989-05-23 | Anderson Mark E | Method for administering interleukin-2 |
US5069216A (en) | 1986-07-03 | 1991-12-03 | Advanced Magnetics Inc. | Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract |
JPS6390534A (ja) | 1986-10-06 | 1988-04-21 | Hitachi Ltd | アルカリ可溶性ラダ−シリコ−ン重合体 |
JPS63101427A (ja) | 1986-10-17 | 1988-05-06 | Hitachi Ltd | アルカリ可溶性ラダ−シリコ−ン |
US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
US4837311A (en) | 1987-06-22 | 1989-06-06 | Hoffman-La Roche Inc. | Anti-retroviral compounds |
US4894231A (en) | 1987-07-28 | 1990-01-16 | Biomeasure, Inc. | Therapeutic agent delivery system |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
JPH01126474U (US20030220297A1-20031127-C00009.png) * | 1988-02-22 | 1989-08-29 | ||
US6146358A (en) * | 1989-03-14 | 2000-11-14 | Cordis Corporation | Method and apparatus for delivery of therapeutic agent |
US4936281A (en) | 1989-04-13 | 1990-06-26 | Everest Medical Corporation | Ultrasonically enhanced RF ablation catheter |
WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
US5182293A (en) | 1989-11-13 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones |
US5067491A (en) | 1989-12-08 | 1991-11-26 | Becton, Dickinson And Company | Barrier coating on blood contacting devices |
DE69108423T2 (de) * | 1990-02-08 | 1995-07-27 | Howmedica | Aufblasbarer Dilatator. |
US6004346A (en) | 1990-02-28 | 1999-12-21 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5545208A (en) | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5195417A (en) | 1990-04-26 | 1993-03-23 | Northern Telecom Limited | Registration of artwork panels in the manufacture of printed circuit boards |
AU7998091A (en) | 1990-05-17 | 1991-12-10 | Harbor Medical Devices, Inc. | Medical device polymer |
DE69110467T2 (de) | 1990-06-15 | 1996-02-01 | Cortrak Medical Inc | Vorrichtung zur abgabe von medikamenten. |
US5112457A (en) | 1990-07-23 | 1992-05-12 | Case Western Reserve University | Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants |
US5163952A (en) | 1990-09-14 | 1992-11-17 | Michael Froix | Expandable polymeric stent with memory and delivery apparatus and method |
US5130307A (en) | 1990-09-28 | 1992-07-14 | American Home Products Corporation | Aminoesters of rapamycin |
US5378696A (en) | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
US5484584A (en) | 1990-10-02 | 1996-01-16 | Board Of Regents, The University Of Texas System | Therapeutic and diagnostic use of modified polymeric microcapsules |
WO1992006992A2 (en) | 1990-10-09 | 1992-04-30 | Merck & Co., Inc. | New process for biophosphorylating organic compounds |
US5893840A (en) | 1991-01-04 | 1999-04-13 | Medtronic, Inc. | Releasable microcapsules on balloon catheters |
US5368557A (en) | 1991-01-11 | 1994-11-29 | Baxter International Inc. | Ultrasonic ablation catheter device having multiple ultrasound transmission members |
WO1993013663A1 (en) | 1992-01-17 | 1993-07-22 | Abbott Laboratories | Method of directing biosynthesis of specific polyketides |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5194447A (en) | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
DE4117782C2 (de) | 1991-05-28 | 1997-07-17 | Diagnostikforschung Inst | Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel |
ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
US5356433A (en) | 1991-08-13 | 1994-10-18 | Cordis Corporation | Biocompatible metal surfaces |
US5176907A (en) | 1991-08-13 | 1993-01-05 | The Johns Hopkins University School Of Medicine | Biocompatible and biodegradable poly (phosphoester-urethanes) |
US5604294A (en) * | 1991-09-05 | 1997-02-18 | Luly; Jay R. | Macrocyclic immunomodulators |
US5252732A (en) * | 1991-09-09 | 1993-10-12 | Merck & Co., Inc. | D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity |
US5411550A (en) | 1991-09-16 | 1995-05-02 | Atrium Medical Corporation | Implantable prosthetic device for the delivery of a bioactive material |
US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
US5286731A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
US5464450A (en) | 1991-10-04 | 1995-11-07 | Scimed Lifesystems Inc. | Biodegradable drug delivery vascular stent |
US5500013A (en) | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
WO1993006792A1 (en) | 1991-10-04 | 1993-04-15 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5225282A (en) | 1991-12-13 | 1993-07-06 | Molecular Bioquest, Inc. | Biodegradable magnetic microcluster comprising non-magnetic metal or metal oxide particles coated with a functionalized polymer |
US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
US5876452A (en) | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
US5656297A (en) | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
US5599352A (en) | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
CA2132636C (en) | 1992-03-30 | 2002-12-17 | Robert P. Waranis | Rapamycin formulation for iv injection |
US5288711A (en) | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
US5283257A (en) | 1992-07-10 | 1994-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating hyperproliferative vascular disease |
MX9304868A (es) * | 1992-08-13 | 1994-05-31 | American Home Prod | 27-hidroxirapamicina, derivados de la misma y composicion farmaceutica que la contiene. |
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5489680A (en) * | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
US5434260A (en) * | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
US5342348A (en) | 1992-12-04 | 1994-08-30 | Kaplan Aaron V | Method and device for treating and enlarging body lumens |
US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
DE69435044T2 (de) | 1993-04-23 | 2008-09-18 | Wyeth | Rapamycin - Konjugate und Antikörper |
US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5387680A (en) * | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
US5409000A (en) | 1993-09-14 | 1995-04-25 | Cardiac Pathways Corporation | Endocardial mapping and ablation system utilizing separately controlled steerable ablation catheter with ultrasonic imaging capabilities and method |
AU688782B2 (en) | 1993-09-30 | 1998-03-19 | Wyeth | Rapamycin formulations for oral administration |
US5616588A (en) | 1993-09-30 | 1997-04-01 | American Home Products Corporation | Rapamycin formulation for IV injection |
US5516770A (en) | 1993-09-30 | 1996-05-14 | American Home Products Corporation | Rapamycin formulation for IV injection |
US5536729A (en) | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
IL111004A (en) | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
US5391730A (en) * | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
US5463010A (en) | 1993-11-12 | 1995-10-31 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Hydrocyclosiloxane membrane prepared by plasma polymerization process |
CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
US5385910A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
WO1995014865A1 (en) | 1993-11-23 | 1995-06-01 | Alliedsignal Inc. | Frictionless resilient bearing mount |
US6150137A (en) | 1994-05-27 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Immunosuppressant target proteins |
US6152141A (en) * | 1994-07-28 | 2000-11-28 | Heartport, Inc. | Method for delivery of therapeutic agents to the heart |
US5660873A (en) | 1994-09-09 | 1997-08-26 | Bioseal, Limited Liability Corporaton | Coating intraluminal stents |
US5891108A (en) | 1994-09-12 | 1999-04-06 | Cordis Corporation | Drug delivery stent |
US5649977A (en) | 1994-09-22 | 1997-07-22 | Advanced Cardiovascular Systems, Inc. | Metal reinforced polymer stent |
JP3942201B2 (ja) | 1994-11-18 | 2007-07-11 | 株式会社カネカ | フェニルポリシルセスキオキサンの製造方法 |
US5491231A (en) * | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
US5665591A (en) * | 1994-12-06 | 1997-09-09 | Trustees Of Boston University | Regulation of smooth muscle cell proliferation |
US5563145A (en) * | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
US5637113A (en) | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
CA2209183A1 (en) | 1994-12-29 | 1996-07-11 | Joel L. Pomerantz | Chimeric dna-binding proteins |
US5496832A (en) | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
US5609629A (en) | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
CA2178541C (en) | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
PT833828E (pt) * | 1995-06-09 | 2003-02-28 | Novartis Ag | Derivados de rapamicina |
AU706445B2 (en) | 1995-07-06 | 1999-06-17 | Brown University Research Foundation | Cell-free synthesis of polyketides |
FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
JP3324360B2 (ja) | 1995-09-25 | 2002-09-17 | 信越化学工業株式会社 | ポリシロキサン化合物及びポジ型レジスト材料 |
US5879808A (en) | 1995-10-27 | 1999-03-09 | Alpha Metals, Inc. | Parylene polymer layers |
US5735811A (en) | 1995-11-30 | 1998-04-07 | Pharmasonics, Inc. | Apparatus and methods for ultrasonically enhanced fluid delivery |
US5725494A (en) | 1995-11-30 | 1998-03-10 | Pharmasonics, Inc. | Apparatus and methods for ultrasonically enhanced intraluminal therapy |
US5728062A (en) | 1995-11-30 | 1998-03-17 | Pharmasonics, Inc. | Apparatus and methods for vibratory intraluminal therapy employing magnetostrictive transducers |
CA2199890C (en) * | 1996-03-26 | 2002-02-05 | Leonard Pinchuk | Stents and stent-grafts having enhanced hoop strength and methods of making the same |
US5928145A (en) | 1996-04-25 | 1999-07-27 | The Johns Hopkins University | Method of magnetic resonance imaging and spectroscopic analysis and associated apparatus employing a loopless antenna |
US5951586A (en) | 1996-05-15 | 1999-09-14 | Medtronic, Inc. | Intraluminal stent |
CN1235608A (zh) | 1996-09-09 | 1999-11-17 | 美国家用产品公司 | 烷基化的雷帕霉素衍生物 |
US6099561A (en) | 1996-10-21 | 2000-08-08 | Inflow Dynamics, Inc. | Vascular and endoluminal stents with improved coatings |
ZA9710342B (en) | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
US5980551A (en) | 1997-02-07 | 1999-11-09 | Endovasc Ltd., Inc. | Composition and method for making a biodegradable drug delivery stent |
US6051276A (en) | 1997-03-14 | 2000-04-18 | Alpha Metals, Inc. | Internally heated pyrolysis zone |
US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
US5843172A (en) | 1997-04-15 | 1998-12-01 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US5985325A (en) | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
HUP0003341A3 (en) | 1997-06-13 | 2001-03-28 | Wyeth Corp | Rapamycin formulations for oral administration |
AU9036198A (en) | 1997-08-26 | 1999-03-16 | Ariad Gene Therapeutics, Inc. | Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain |
US5780604A (en) * | 1997-09-26 | 1998-07-14 | Abbott Laboratories | 11,12-cyclic phosphite or phosphate derivatives of erythromycin and related macrolides |
US5972027A (en) | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
US6031375A (en) | 1997-11-26 | 2000-02-29 | The Johns Hopkins University | Method of magnetic resonance analysis employing cylindrical coordinates and an associated apparatus |
US6623521B2 (en) | 1998-02-17 | 2003-09-23 | Md3, Inc. | Expandable stent with sliding and locking radial elements |
US7208010B2 (en) | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US5980566A (en) | 1998-04-11 | 1999-11-09 | Alt; Eckhard | Vascular and endoluminal stents with iridium oxide coating |
US8029561B1 (en) | 2000-05-12 | 2011-10-04 | Cordis Corporation | Drug combination useful for prevention of restenosis |
US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
AU4543899A (en) * | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
US6087064A (en) | 1998-09-03 | 2000-07-11 | International Business Machines Corporation | Silsesquioxane polymers, method of synthesis, photoresist composition, and multilayer lithographic method |
US6063101A (en) | 1998-11-20 | 2000-05-16 | Precision Vascular Systems, Inc. | Stent apparatus and method |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
EP1180013B1 (en) | 1999-05-27 | 2006-03-08 | Biocompatibles UK Limited | Local drug delivery |
EP1190277B1 (en) | 1999-06-10 | 2009-10-07 | AlliedSignal Inc. | Semiconductor having spin-on-glass anti-reflective coatings for photolithography |
US6890448B2 (en) | 1999-06-11 | 2005-05-10 | Shipley Company, L.L.C. | Antireflective hard mask compositions |
DE60009493T2 (de) | 1999-06-24 | 2005-03-17 | Abbott Vascular Devices Ltd. | Mittels eines ballons expandierbarer stent |
JP4187879B2 (ja) | 1999-08-06 | 2008-11-26 | 東京応化工業株式会社 | 感放射線レジスト組成物 |
US6471979B2 (en) | 1999-12-29 | 2002-10-29 | Estrogen Vascular Technology, Llc | Apparatus and method for delivering compounds to a living organism |
US20010007083A1 (en) | 1999-12-29 | 2001-07-05 | Roorda Wouter E. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
US6899731B2 (en) | 1999-12-30 | 2005-05-31 | Boston Scientific Scimed, Inc. | Controlled delivery of therapeutic agents by insertable medical devices |
EP1250164B1 (en) | 2000-01-24 | 2005-11-23 | Biocompatibles UK Limited | Coated implants |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
JP4994558B2 (ja) | 2000-05-12 | 2012-08-08 | コーディス・コーポレイション | 脈管の病気の治療のための配給装置 |
US20020013335A1 (en) | 2000-06-16 | 2002-01-31 | American Home Products Corporation | Method of treating cardiovascular disease |
US7205284B2 (en) | 2000-07-10 | 2007-04-17 | University Of Mississippi | Potent immunostimulants from microalgae |
JP4622061B2 (ja) | 2000-07-27 | 2011-02-02 | Jsr株式会社 | レジスト下層膜用組成物およびその製造方法 |
TW556047B (en) | 2000-07-31 | 2003-10-01 | Shipley Co Llc | Coated substrate, method for forming photoresist relief image, and antireflective composition |
JP4141625B2 (ja) | 2000-08-09 | 2008-08-27 | 東京応化工業株式会社 | ポジ型レジスト組成物およびそのレジスト層を設けた基材 |
ATE278421T1 (de) | 2000-08-11 | 2004-10-15 | Wyeth Corp | Verfahren zur behandlung eines östrogenrezeptor positives karzinoms |
EP1319008B1 (en) | 2000-09-19 | 2008-10-15 | Wyeth | Water soluble rapamycin esters |
TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
US20030033007A1 (en) * | 2000-12-22 | 2003-02-13 | Avantec Vascular Corporation | Methods and devices for delivery of therapeutic capable agents with variable release profile |
GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
GB0100760D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
WO2002066092A2 (en) | 2001-02-23 | 2002-08-29 | Angiogene Inc. | Drug eluting device for treating vascular diseases |
ES2312568T3 (es) | 2001-04-06 | 2009-03-01 | Wyeth | Combinaciones antineoplasicas que comprenden cci-779 (derivado de rapamicina) junto con gemcitabina o fluoruracilo. |
TW594416B (en) | 2001-05-08 | 2004-06-21 | Shipley Co Llc | Photoimageable composition |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
KR20040076278A (ko) | 2002-01-10 | 2004-08-31 | 노파르티스 아게 | 라파마이신 및 그의 유도체를 포함하는, 혈관 질환의 예방및 치료를 위한 약물 전달 시스템 |
CN100522967C (zh) * | 2002-02-01 | 2009-08-05 | 阿里亚德基因治疗公司 | 含磷化合物及其应用 |
US7432277B2 (en) * | 2002-02-01 | 2008-10-07 | Araid Gene Therapeutics, Inc. | Phosphorus-containing macrocycles |
JP4557497B2 (ja) | 2002-03-03 | 2010-10-06 | ローム・アンド・ハース・エレクトロニック・マテリアルズ,エル.エル.シー. | シランモノマー及びポリマーを製造する方法及びそれを含むフォトレジスト組成物 |
WO2004004644A2 (en) * | 2002-07-05 | 2004-01-15 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
EP1539041A1 (en) * | 2002-07-25 | 2005-06-15 | Avantec Vascular Corporation | Devices delivering therapeutic agents and methods regarding the same |
WO2004011998A1 (en) * | 2002-07-26 | 2004-02-05 | Samsung Electronics Co., Ltd. | Upper substrate, liquid crystal display apparatus having the same and method of fabricating the same |
CN100415233C (zh) | 2002-09-17 | 2008-09-03 | 惠氏公司 | 口服制剂 |
WO2005016252A2 (en) * | 2003-07-11 | 2005-02-24 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing macrocycles |
SG135193A1 (en) | 2003-08-18 | 2007-09-28 | Pfizer Prod Inc | Dosing schedule for erbb2 anticancer agents |
AR045957A1 (es) | 2003-10-03 | 2005-11-16 | Novartis Ag | Composicion farmaceutica y combinacion |
GB0327840D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
MX2007003790A (es) | 2004-09-30 | 2007-05-24 | Ariad Gene Therapeutics Inc | Metodo de tratamiento. |
MX2007005153A (es) | 2004-10-28 | 2007-06-26 | Wyeth Corp | Uso de un inhibidor del mtor en el tratamiento de leiomioma del utero. |
WO2006069038A1 (en) | 2004-12-20 | 2006-06-29 | Ariad Gene Therapeutics, Inc. | Therapeutic materials and methods |
US20060160837A1 (en) | 2004-12-29 | 2006-07-20 | The Brigham And Women's Hospital, Inc. | Rapamycin compounds in the treatment of neurofibromatosis type 1 |
JP2008530145A (ja) | 2005-02-15 | 2008-08-07 | ワイス | 経口投与可能なcci−779製剤 |
US20070004767A1 (en) * | 2005-06-30 | 2007-01-04 | Gutmann David H | Methods for treating neurofibromatosis 1 |
TW200803842A (en) | 2005-11-04 | 2008-01-16 | Wyeth Corp | Antineoplastic combinations of temsirolimus and sunitinib malate |
DE102010042183A1 (de) | 2010-10-08 | 2012-04-12 | Robert Bosch Gmbh | Hybridantriebseinrichtung |
TWM483731U (zh) | 2013-12-31 | 2014-08-11 | Yong-Hua Chen | 辦公椅結構 |
US9408008B2 (en) | 2014-02-28 | 2016-08-02 | Sonos, Inc. | Playback zone representations |
US20160120174A1 (en) | 2014-10-29 | 2016-05-05 | Ronald Steven Cok | Imprinted multi-layer biocidal particle structure |
-
2003
- 2003-02-03 CN CNB03807799XA patent/CN100522967C/zh not_active Expired - Lifetime
- 2003-02-03 EP EP20030735110 patent/EP1478648B1/en not_active Expired - Lifetime
- 2003-02-03 EA EA200401008A patent/EA008379B1/ru not_active IP Right Cessation
- 2003-02-03 AU AU2003210787A patent/AU2003210787B2/en not_active Ceased
- 2003-02-03 CN CN200910149994.2A patent/CN101717410B/zh not_active Expired - Lifetime
- 2003-02-03 CA CA2472341A patent/CA2472341C/en not_active Expired - Fee Related
- 2003-02-03 JP JP2003564006A patent/JP4547911B2/ja not_active Expired - Lifetime
- 2003-02-03 EA EA200700193A patent/EA011488B1/ru not_active IP Right Cessation
- 2003-02-03 MX MXPA04007402A patent/MXPA04007402A/es active IP Right Grant
- 2003-02-03 BR BR0307544A patent/BR0307544A/pt not_active Application Discontinuation
- 2003-02-03 US US10/357,152 patent/US20030220297A1/en not_active Abandoned
- 2003-02-03 PL PL371526A patent/PL216224B1/pl unknown
- 2003-02-03 PT PT03735110T patent/PT1478648E/pt unknown
- 2003-02-03 WO PCT/US2003/003030 patent/WO2003064383A2/en active Application Filing
- 2003-02-03 ES ES03735110.3T patent/ES2485841T3/es not_active Expired - Lifetime
- 2003-02-03 KR KR20047011867A patent/KR100956195B1/ko active IP Right Grant
- 2003-02-03 IL IL16273403A patent/IL162734A0/xx unknown
- 2003-02-03 DK DK03735110T patent/DK1478648T3/da active
- 2003-02-03 EP EP20110180546 patent/EP2407473A3/en not_active Withdrawn
- 2003-02-03 KR KR1020097022486A patent/KR101004224B1/ko active IP Right Grant
- 2003-08-06 US US10/635,054 patent/US20040073024A1/en not_active Abandoned
-
2004
- 2004-06-04 US US10/862,149 patent/US7091213B2/en not_active Expired - Lifetime
- 2004-06-24 IL IL162734A patent/IL162734A/en active IP Right Grant
-
2006
- 2006-07-27 US US11/494,418 patent/US7186826B2/en not_active Expired - Lifetime
-
2007
- 2007-01-05 US US11/650,017 patent/US7709020B2/en not_active Expired - Lifetime
-
2009
- 2009-06-04 IL IL199153A patent/IL199153A/en active IP Right Grant
- 2009-07-20 AU AU2009202913A patent/AU2009202913B2/en not_active Ceased
-
2010
- 2010-04-06 US US12/798,501 patent/US8058426B2/en not_active Expired - Fee Related
-
2011
- 2011-11-14 US US13/295,826 patent/US9024014B2/en not_active Expired - Fee Related
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683195B1 (US20030220297A1-20031127-C00009.png) | 1986-01-30 | 1990-11-27 | Cetus Corp | |
WO1994018317A1 (en) | 1993-02-12 | 1994-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
US5310903A (en) | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | Imidazolidyl rapamycin derivatives |
WO1995002684A1 (en) | 1993-07-16 | 1995-01-26 | The Board Of Trustees Of The Leland Stanford Junior University | Regulated apoptosis |
US5527907A (en) | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
US5525610A (en) | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
WO1998009972A1 (en) | 1996-09-09 | 1998-03-12 | American Home Products Corporation | Rapamycin derivatives with unnatural stereochemistries |
WO1999036553A2 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
WO2001004387A1 (en) | 1999-07-12 | 2001-01-18 | Semitool, Inc. | Lift and rotate assembly for use in a workpiece processing station and a method of attaching the same |
WO2001014387A1 (en) | 1999-08-24 | 2001-03-01 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
US6471980B2 (en) | 2000-12-22 | 2002-10-29 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
Non-Patent Citations (27)
Title |
---|
"Culture Of Animal Cells", 1987, ALAN R. LISS, INC. |
"DNA Cloning", vol. I, II, 1985 |
"Gene Transfer Vectors For Mammalian Cells", 1987, COLD SPRING HARBOR LABORATORY |
"Handbook Of Experimental Immunology", vol. I-IV, 1986 |
"Immobilized Cells And Enzymes", 1986, IRL PRESS |
"Immunochemical Methods In Cell And Molecular Biology", 1987, ACADEMIC PRESS |
"Manipulating the Mouse Embryo", 1986, COLD SPRING HARBOR LABORATORY PRESS |
"Methods In Enzymology", ACADEMIC PRESS, INC. |
"Methods In Enzymology", vol. 154, 155 |
"Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
"Nucleic Acid Hybridization", 1984 |
"Oligonucleotide Synthesis", 1984 |
"Transcription And Translation", 1984 |
B. PERBAL: "A Practical Guide To Molecular Cloning", 1984 |
BRAVO, F ET AL., TETRAHEDRON: ASYMMETRY, vol. 12, 2001, pages 1635 - 1643 |
DANCEY, HEMATOL ONCOL CLIN N AM, vol. 16, 2002, pages 1101 - 1114 |
GEOERGER, B. ET AL., CANCER RES., vol. 61, 2001, pages 1527 - 1532 |
MASSON S ET AL., BULL SOC CHIM FR, vol. 133, 1996, pages 951 - 964 |
RAJASUBRAMANIAN ET AL., ASAIO JOURNAL, vol. 40, 1994, pages M584 - 589 |
RIVERA VM; YE X; COURAGE NL; SACHAR J; CERASOLI F; WILSON JM; GILMAN M: "Long-term regulated expression of growth hormone in mice following intramuscular gene transfer", PROC NATL ACAD SCI USA, vol. 96, 1999, pages 8657 - 8662 |
See also references of EP1478648A4 |
WANG M ET AL., J ORG CHEM, vol. 60, 1995, pages 7364 - 7365 |
YAMASHITA, M. ET AL., BULL CHEM SOC JAPAN, vol. 56, 1983, pages 1871 - 1872 |
YE X; RIVERA VM; ZOLTICK P; CERASOLI F JR; SCHNELL MA; GAO G-P; HUGHES JV; GILMAN M; WILSON JM: "Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer", SCIENCE, vol. 283, 1999, pages 88 - 91, XP002977065, DOI: doi:10.1126/science.283.5398.88 |
YU, K. ET AL., ENDOCRINE-RELATED CANCER, vol. 8, 2001, pages 249 - 258 |
YUAN ET AL., SYNTHESIS, vol. 1, 1989, pages 48 - 50 |
ZHAO, K. ET AL., TETRAHEDRON, vol. 49, 1993, pages 363 - 368 |
Cited By (265)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7091213B2 (en) | 2002-02-01 | 2006-08-15 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing compounds and uses thereof |
US9024014B2 (en) | 2002-02-01 | 2015-05-05 | Ariad Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
US8058426B2 (en) | 2002-02-01 | 2011-11-15 | Ariad Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
US7709020B2 (en) | 2002-02-01 | 2010-05-04 | Ariad Pharmaceuticals, Inc. | Implantable device comprising phosphorus-containing macrolides |
US7432277B2 (en) | 2002-02-01 | 2008-10-07 | Araid Gene Therapeutics, Inc. | Phosphorus-containing macrocycles |
US7186826B2 (en) * | 2002-02-01 | 2007-03-06 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing compounds and uses thereof |
US7649015B2 (en) | 2002-04-26 | 2010-01-19 | Gilead Sciences, Inc. | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds |
US7462608B2 (en) | 2002-04-26 | 2008-12-09 | Gilead Sciences, Inc. | Non nucleoside reverse transcriptase inhibitors |
US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
US7300924B2 (en) | 2003-04-25 | 2007-11-27 | Gilead Sciences, Inc. | Anti-infective phosphonate analogs |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
US8871785B2 (en) | 2003-04-25 | 2014-10-28 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
US7645747B2 (en) | 2003-04-25 | 2010-01-12 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
US9139604B2 (en) | 2003-04-25 | 2015-09-22 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
WO2004096236A3 (en) * | 2003-04-25 | 2005-06-30 | Gilead Sciences Inc | Immunomodulator phosphonate conjugates |
US7273716B2 (en) | 2003-04-25 | 2007-09-25 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds with GS-7340 ester hydrolase |
US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
US7429565B2 (en) | 2003-04-25 | 2008-09-30 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
US7427636B2 (en) | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
WO2004096236A2 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Immunomodulator phosphonate conjugates |
US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
US8022083B2 (en) | 2003-04-25 | 2011-09-20 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
US7417055B2 (en) | 2003-04-25 | 2008-08-26 | Gilead Sciences, Inc. | Kinase inhibitory phosphonate analogs |
EP1648900A2 (en) * | 2003-07-11 | 2006-04-26 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing macrocycles |
EP1648900A4 (en) * | 2003-07-11 | 2010-02-10 | Ariad Pharma Inc | PHOSPHORUS MACROCYCLES |
US7273717B2 (en) | 2003-10-24 | 2007-09-25 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B |
US7432273B2 (en) | 2003-10-24 | 2008-10-07 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
US7427624B2 (en) | 2003-10-24 | 2008-09-23 | Gilead Sciences, Inc. | Purine nucleoside phosphorylase inhibitory phosphonate compounds |
US7273715B2 (en) | 2003-10-24 | 2007-09-25 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase A |
WO2005049021A1 (en) * | 2003-11-03 | 2005-06-02 | Oy Helsinki Transplantation R & D Ltd | Materials and methods for inhibiting neointimal hyperplasia |
US8507518B2 (en) | 2003-11-04 | 2013-08-13 | Mayo Foundation For Medical Education And Research | Method of treating mantle cell lymphoma |
WO2005053661A2 (en) * | 2003-12-01 | 2005-06-16 | Novartis Ag | Pharmaceutical combinations |
WO2005053661A3 (en) * | 2003-12-01 | 2005-12-29 | Novartis Ag | Pharmaceutical combinations |
AU2004294282B2 (en) * | 2003-12-01 | 2009-05-07 | Novartis Ag | Pharmaceutical combinations |
EP1543849A1 (en) * | 2003-12-17 | 2005-06-22 | Cordis Neurovascular, Inc. | Activatable bioactive implantable medical device |
EP1543850A1 (en) * | 2003-12-17 | 2005-06-22 | Cordis Neurovascular, Inc. | Activatable bioactive implantable medical device |
EP1557182A1 (en) * | 2003-12-17 | 2005-07-27 | Cordis Neurovascular, Inc. | Activatable bioactive implantable medical device |
US7432272B2 (en) | 2003-12-22 | 2008-10-07 | Gilead Sciences, Inc. | Antiviral analogs |
US7244261B2 (en) | 2004-04-08 | 2007-07-17 | Cordis Neurovascular, Inc. | Activatable bioactive vascular occlusive device |
US7247159B2 (en) | 2004-04-08 | 2007-07-24 | Cordis Neurovascular, Inc. | Activatable bioactive vascular occlusive device |
US9457035B2 (en) | 2004-07-27 | 2016-10-04 | Gilead Sciences, Inc. | Antiviral compounds |
JP2008532991A (ja) * | 2005-03-11 | 2008-08-21 | バイオティカ テクノロジー リミテッド | ラパマイシンの39−デスメトキシ誘導体 |
EP2206704A1 (en) | 2005-04-19 | 2010-07-14 | Novartis AG | Pharmaceutically active diazepanes |
WO2006128660A1 (en) * | 2005-05-31 | 2006-12-07 | Novartis Ag | Combination of hmg-coa reductase inhibitors amd mtor inhibitors |
EP2332577A1 (en) | 2005-10-26 | 2011-06-15 | Novartis AG | Novel use of IL-1beta compounds |
EP2662082A1 (en) | 2005-11-14 | 2013-11-13 | Ariad Pharmaceuticals, Incorporated | Administration of mTOR inhibitors |
EP2022498A2 (en) | 2005-11-21 | 2009-02-11 | Novartis AG | Neuroendocrine tumour treatment |
EP2275103A2 (en) | 2005-11-21 | 2011-01-19 | Novartis AG | mTOR inhibitors in the treatment of endocrine tumors |
WO2007135411A1 (en) * | 2006-05-19 | 2007-11-29 | Biotica Technology Ltd. | 39-desmethoxy-39-methyl derivatives of rapamycin. |
US7897608B2 (en) | 2006-05-19 | 2011-03-01 | Biotica Technology Limited | 39-desmethoxy-39-methyl derivatives of rapamycin |
EP2083834A4 (en) * | 2006-09-13 | 2010-11-10 | Elixir Medical Corp | MACROCYCLIC LACTON COMPOUNDS AND METHOD FOR THEIR USE |
US10695327B2 (en) | 2006-09-13 | 2020-06-30 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
US8088789B2 (en) | 2006-09-13 | 2012-01-03 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
US10123996B2 (en) | 2006-09-13 | 2018-11-13 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
US9149470B2 (en) | 2006-09-13 | 2015-10-06 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
WO2008033956A2 (en) | 2006-09-13 | 2008-03-20 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
EP2083834A2 (en) * | 2006-09-13 | 2009-08-05 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
US8404641B2 (en) | 2006-09-13 | 2013-03-26 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
US8367081B2 (en) | 2006-09-13 | 2013-02-05 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
US8496967B2 (en) | 2006-11-14 | 2013-07-30 | Ariad Pharmaceuticals, Inc. | Oral formulations |
EP2468302A1 (en) | 2007-05-29 | 2012-06-27 | Novartis AG | New indications for anti-IL-1beta therapy |
EP4177268A2 (en) | 2007-05-29 | 2023-05-10 | Novartis AG | New indications for anti-il-1beta therapy |
EP2468301A1 (en) | 2007-05-29 | 2012-06-27 | Novartis AG | New indications for anti-IL-1-beta therapy |
WO2009054001A1 (en) * | 2007-10-22 | 2009-04-30 | Biocon Limited | A pharmaceutical composition and a process thereof |
US8921642B2 (en) | 2008-01-11 | 2014-12-30 | Massachusetts Eye And Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
US8951986B2 (en) | 2008-07-08 | 2015-02-10 | Gilead Sciences, Inc. | Salts of HIV inhibitor compounds |
US9381206B2 (en) | 2008-07-08 | 2016-07-05 | Gilead Sciences, Inc. | Salts of HIV inhibitor compounds |
US9783568B2 (en) | 2008-07-08 | 2017-10-10 | Gilead Sciences, Inc. | Salts of HIV inhibitor compounds |
WO2011002887A1 (en) | 2009-07-02 | 2011-01-06 | Schering Corporation | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS |
WO2011024168A2 (en) | 2009-08-26 | 2011-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd | Sustained release delivery systems for the prevention and treatment of head and neck cancers |
WO2011050016A1 (en) | 2009-10-23 | 2011-04-28 | Eli Lilly And Company | Akt inhibitors |
EP2762142A1 (en) | 2009-10-30 | 2014-08-06 | ARIAD Pharmaceuticals, Inc. | Compositions for treating cancer |
WO2011120911A1 (en) | 2010-03-30 | 2011-10-06 | Novartis Ag | Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling |
WO2012022814A1 (en) | 2010-08-20 | 2012-02-23 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
WO2012027236A1 (en) | 2010-08-23 | 2012-03-01 | Schering Corporation | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
WO2012061907A2 (en) | 2010-11-10 | 2012-05-18 | Katholieke Universiteit Leuven | Osteoclast activity |
EP2455104A1 (en) | 2010-11-19 | 2012-05-23 | Universitätsklinikum Freiburg | Bio-functionalized stimulus-responsive dissolvable PEG-hydrogels |
WO2012065751A1 (en) | 2010-11-19 | 2012-05-24 | Universitätsklinikum Freiburg | Bio-functionalized stimulus-responsive dissolvable peg-hydrogels |
WO2012145471A1 (en) | 2011-04-21 | 2012-10-26 | Merck Sharp & Dohme Corp. | Insulin-like growth factor-1 receptor inhibitors |
WO2013016164A1 (en) | 2011-07-26 | 2013-01-31 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS |
WO2013082282A1 (en) | 2011-12-02 | 2013-06-06 | lNOVARTIS AG | Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease. |
EP3590538A1 (en) | 2011-12-05 | 2020-01-08 | Novartis AG | Antibodies for epidermal growth factor receptor 3 (her3) |
WO2013084147A2 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
WO2013084138A1 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Cyclic urea derivatives as androgen receptor antagonists |
WO2013084148A2 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
US10023862B2 (en) | 2012-01-09 | 2018-07-17 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat beta-catenin-related diseases |
WO2013105022A2 (en) | 2012-01-09 | 2013-07-18 | Novartis Ag | Organic compositions to treat beta-catenin-related diseases |
WO2013138871A1 (en) | 2012-03-23 | 2013-09-26 | The University Of Queensland | Immunomodulatory agent and uses therefor |
EP3360870A1 (en) | 2013-02-19 | 2018-08-15 | Novartis AG | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
WO2014130657A1 (en) | 2013-02-20 | 2014-08-28 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
EP3626741A1 (en) | 2013-02-20 | 2020-03-25 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
WO2014160160A2 (en) | 2013-03-13 | 2014-10-02 | Novartis Ag | Antibody drug conjugates |
EP3514178A1 (en) | 2013-03-15 | 2019-07-24 | Novartis AG | Antibody drug conjugates |
EP4067382A1 (en) | 2013-03-16 | 2022-10-05 | Novartis AG | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor |
EP3539986A1 (en) | 2013-03-16 | 2019-09-18 | Novartis AG | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor |
WO2014153270A1 (en) | 2013-03-16 | 2014-09-25 | Novartis Ag | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor |
WO2014184734A1 (en) | 2013-05-14 | 2014-11-20 | Novartis Ag | Markers associated with mtor inhibition |
WO2015044854A1 (en) | 2013-09-24 | 2015-04-02 | Novartis Ag | Markers associated with mtor inhibition |
EP2878312A1 (en) | 2013-12-02 | 2015-06-03 | Albert-Ludwigs-Universität Freiburg | Reversible PEGylation of nanocarriers |
WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
WO2015090230A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
EP4026909A1 (en) | 2013-12-19 | 2022-07-13 | Novartis AG | Human mesothelin chimeric antigen receptors and uses thereof |
WO2015107493A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
WO2015107495A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
EP3514179A1 (en) | 2014-01-24 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
EP4324518A2 (en) | 2014-01-31 | 2024-02-21 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
EP3660050A1 (en) | 2014-03-14 | 2020-06-03 | Novartis AG | Antibody molecules to lag-3 and uses thereof |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
WO2015187541A1 (en) | 2014-06-02 | 2015-12-10 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
EP3539990A1 (en) | 2014-07-16 | 2019-09-18 | Dana-Farber Cancer Institute, Inc. | Her3 inhibition in low-grade serous cancers |
EP3722316A1 (en) | 2014-07-21 | 2020-10-14 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
EP3660042A1 (en) | 2014-07-31 | 2020-06-03 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
WO2016024195A1 (en) | 2014-08-12 | 2016-02-18 | Novartis Ag | Anti-cdh6 antibody drug conjugates |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
EP3659621A1 (en) | 2014-09-13 | 2020-06-03 | Novartis AG | Combination therapies for cancer |
EP3925622A1 (en) | 2014-09-13 | 2021-12-22 | Novartis AG | Combination therapies |
WO2016040880A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
WO2016040892A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies |
EP3967709A1 (en) | 2014-09-17 | 2022-03-16 | Novartis AG | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
WO2016044605A1 (en) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
WO2016054555A2 (en) | 2014-10-03 | 2016-04-07 | Novartis Ag | Combination therapies |
EP3662903A2 (en) | 2014-10-03 | 2020-06-10 | Novartis AG | Combination therapies |
WO2016057841A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Compositions and methods of use for augmented immune response and cancer therapy |
WO2016057705A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
EP4245376A2 (en) | 2014-10-14 | 2023-09-20 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
WO2016075670A1 (en) | 2014-11-14 | 2016-05-19 | Novartis Ag | Antibody drug conjugates |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
WO2016151499A1 (en) | 2015-03-25 | 2016-09-29 | Novartis Ag | Formylated n-heterocyclic derivatives as fgfr4 inhibitors |
WO2016164580A1 (en) | 2015-04-07 | 2016-10-13 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
EP4056588A1 (en) | 2015-04-08 | 2022-09-14 | Novartis AG | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell |
WO2016164731A2 (en) | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
WO2016203432A1 (en) | 2015-06-17 | 2016-12-22 | Novartis Ag | Antibody drug conjugates |
WO2016203405A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2016203406A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2016203404A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2017015427A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
WO2017019894A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
EP3964528A1 (en) | 2015-07-29 | 2022-03-09 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
EP3797797A1 (en) | 2015-10-29 | 2021-03-31 | Novartis AG | Antibody conjugates comprising toll-like receptor agonist |
WO2017072662A1 (en) | 2015-10-29 | 2017-05-04 | Novartis Ag | Antibody conjugates comprising toll-like receptor agonist |
WO2017079115A1 (en) | 2015-11-03 | 2017-05-11 | Janssen Biotech, Inc. | Antibodies specifically binding tim-3 and their uses |
WO2017079116A2 (en) | 2015-11-03 | 2017-05-11 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and tim-3 and their uses |
WO2017079112A1 (en) | 2015-11-03 | 2017-05-11 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
EP4046655A1 (en) | 2015-11-03 | 2022-08-24 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
US10894830B2 (en) | 2015-11-03 | 2021-01-19 | Janssen Biotech, Inc. | Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses |
WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
WO2017112741A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
US10577362B2 (en) | 2016-05-04 | 2020-03-03 | Genoscience Pharma | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases |
WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2018057585A1 (en) | 2016-09-21 | 2018-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use |
WO2018064076A1 (en) | 2016-09-27 | 2018-04-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
US11655282B2 (en) | 2016-09-27 | 2023-05-23 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
EP4089116A1 (en) | 2016-09-27 | 2022-11-16 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
WO2018163051A1 (en) | 2017-03-06 | 2018-09-13 | Novartis Ag | Methods of treatment of cancer with reduced ubb expression |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
WO2018198091A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Antibody conjugates comprising toll-like receptor agonist and combination therapies |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
WO2018215936A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
WO2018215938A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
WO2018226336A1 (en) | 2017-06-09 | 2018-12-13 | Providence Health & Services - Oregon | Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
WO2018237157A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF |
US10851125B2 (en) | 2017-08-01 | 2020-12-01 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate |
WO2019051469A1 (en) | 2017-09-11 | 2019-03-14 | Krouzon Pharmaceuticals, Inc. | SHP2 OCTAHYDROCYCLOPENTA [C] PYRROLE ALLOSTERIC INHIBITORS |
US10435389B2 (en) | 2017-09-11 | 2019-10-08 | Krouzon Pharmaccuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2 |
US11708423B2 (en) | 2017-09-26 | 2023-07-25 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules and methods of use |
WO2019067328A1 (en) | 2017-09-26 | 2019-04-04 | Cero Therapeutics, Inc. | CHIMERIC ENGINEERING RECEPTOR MOLECULES AND METHODS OF USE |
WO2019108900A1 (en) | 2017-11-30 | 2019-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
WO2019152660A1 (en) | 2018-01-31 | 2019-08-08 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
WO2019191339A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof |
WO2019191340A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Cellular immunotherapy compositions and uses thereof |
WO2019191334A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019224718A2 (en) | 2018-05-24 | 2019-11-28 | Janssen Biotech, Inc. | Psma binding agents and uses thereof |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
WO2019229658A1 (en) | 2018-05-30 | 2019-12-05 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
WO2019229701A2 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
WO2019241426A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
EP4306111A2 (en) | 2018-07-10 | 2024-01-17 | Novartis AG | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020012337A1 (en) | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases |
WO2020012334A1 (en) | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
WO2020021322A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) Srl | Stable, concentrated radionuclide complex solutions |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
US11518772B2 (en) | 2018-09-18 | 2022-12-06 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors |
US10894797B2 (en) | 2018-09-18 | 2021-01-19 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors |
US11459340B2 (en) | 2018-09-18 | 2022-10-04 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors |
WO2020061101A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
US11034705B2 (en) | 2018-09-18 | 2021-06-15 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors |
WO2020061103A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
US11034672B1 (en) | 2018-09-25 | 2021-06-15 | Black Diamond Therapeutics, Inc. | Tyrosine kinase inhibitor compositions, methods of making and methods of use |
WO2020068873A1 (en) | 2018-09-25 | 2020-04-02 | Black Diamond Therapeutics, Inc. | Tyrosine kinase inhibitor compositions, methods of making and methods of use |
WO2020064693A1 (en) | 2018-09-25 | 2020-04-02 | Advanced Accelerator Applications (Italy) Srl | Combination therapy |
WO2020069409A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
WO2020069405A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
EP4282416A2 (en) | 2018-09-29 | 2023-11-29 | Novartis AG | Process of manufacture of a compound for inhibiting the activity of shp2 |
WO2020065453A1 (en) | 2018-09-29 | 2020-04-02 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
WO2020088631A1 (en) | 2018-11-01 | 2020-05-07 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020198077A1 (en) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
US11712433B2 (en) | 2019-03-22 | 2023-08-01 | Sumitomo Pharma Oncology, Inc. | Compositions comprising PKM2 modulators and methods of treatment using the same |
WO2021003417A1 (en) | 2019-07-03 | 2021-01-07 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
WO2021030711A1 (en) | 2019-08-15 | 2021-02-18 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
WO2021067875A1 (en) | 2019-10-03 | 2021-04-08 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
WO2021123996A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
WO2021183318A2 (en) | 2020-03-09 | 2021-09-16 | President And Fellows Of Harvard College | Methods and compositions relating to improved combination therapies |
WO2021195206A1 (en) | 2020-03-24 | 2021-09-30 | Black Diamond Therapeutics, Inc. | Polymorphic forms and related uses |
WO2021220170A1 (en) | 2020-04-29 | 2021-11-04 | Novartis Ag | Compounds and compositions for inhibiting the activity of hif2-alpha and their methods of use |
WO2021242794A2 (en) | 2020-05-29 | 2021-12-02 | President And Fellows Of Harvard College | Living cells engineered with polyphenol-functionalized biologically active nanocomplexes |
WO2021252920A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2021262969A1 (en) | 2020-06-24 | 2021-12-30 | The General Hospital Corporation | Materials and methods of treating cancer |
WO2022029573A1 (en) | 2020-08-03 | 2022-02-10 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2022036285A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase |
WO2022036265A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Chimeric tim receptors and uses thereof |
WO2022036287A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Anti-cd72 chimeric receptors and uses thereof |
WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
WO2022123316A1 (en) | 2020-12-09 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
US11746103B2 (en) | 2020-12-10 | 2023-09-05 | Sumitomo Pharma Oncology, Inc. | ALK-5 inhibitors and uses thereof |
WO2022140472A1 (en) | 2020-12-22 | 2022-06-30 | Nikang Therapeutics, Inc. | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway |
WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
WO2022162518A2 (en) | 2021-01-28 | 2022-08-04 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
WO2022170052A1 (en) | 2021-02-05 | 2022-08-11 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof |
WO2022183072A1 (en) | 2021-02-26 | 2022-09-01 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
WO2022215011A1 (en) | 2021-04-07 | 2022-10-13 | Novartis Ag | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
WO2022221227A1 (en) | 2021-04-13 | 2022-10-20 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
WO2022219412A1 (en) | 2021-04-14 | 2022-10-20 | Monte Rosa Therapeutics Ag | Isoindolinone amide compounds useful to treat diseases associated with gspt1 |
WO2022219407A1 (en) | 2021-04-14 | 2022-10-20 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
WO2022243846A1 (en) | 2021-05-18 | 2022-11-24 | Novartis Ag | Combination therapies |
WO2022261018A1 (en) | 2021-06-07 | 2022-12-15 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
WO2023284730A1 (en) | 2021-07-14 | 2023-01-19 | Nikang Therapeutics, Inc. | Alkylidene derivatives as kras inhibitors |
WO2023288046A1 (en) | 2021-07-15 | 2023-01-19 | President And Fellows Of Harvard College | Compositions and methods relating to cells with adhered particles |
WO2023010097A1 (en) | 2021-07-28 | 2023-02-02 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
WO2023192801A1 (en) | 2022-03-28 | 2023-10-05 | Nikang Therapeutics, Inc. | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2023240024A1 (en) | 2022-06-08 | 2023-12-14 | Nikang Therapeutics, Inc. | Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors |
WO2024023666A1 (en) | 2022-07-26 | 2024-02-01 | Novartis Ag | Crystalline forms of an akr1c3 dependent kars inhibitor |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2472341C (en) | Phosphorus-containing compounds & uses thereof | |
AU2003210787A1 (en) | Phosphorus-containing compounds & uses thereof | |
JP2005516065A6 (ja) | リン含有化合物およびその用途 | |
US20050026868A1 (en) | Phosphorus-containing macrocycles | |
AU2013296627C1 (en) | Deuterated ibrutinib | |
CA2910133C (en) | Modified drugs for use in liposomal nanoparticles | |
PL183178B1 (pl) | Pochodne rapamycyny oraz kompozycja farmaceutyczna zawierająca takie pochodne | |
KR20090035716A (ko) | 라파마이신 유사체의 결정형 형태 | |
EA032415B1 (ru) | Замещенные бициклические соединения | |
US7432277B2 (en) | Phosphorus-containing macrocycles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 162734 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2472341 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003210787 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003564006 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/007402 Country of ref document: MX Ref document number: 1020047011867 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003735110 Country of ref document: EP Ref document number: 200401008 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003807799X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003735110 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097022486 Country of ref document: KR |